ALKS

Alkermes Plc. Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Alkermes Plc. is a global biopharmaceutical company focused on neuroscience. The quarter was defined by the completion of the Avadel Pharmaceuticals plc acquisition on February 12, 2026. This transaction added the narcolepsy treatment LUMRYZ to Alkermes' commercial portfolio and integrated Avadel's commercial organization. The company operates as a single reportable segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by $86.4 million (28.2%). Product sales, net, rose to $338.1 million, driven by the inclusion of LUMRYZ ($39.5 million) and volume/price increases for core products (VIVITROL, ARISTADA, LYBALVI). Manufacturing and royalty revenues decreased by $7.2 million due to the conclusion of VUMERITY manufacturing obligations.
• Profitability Decline: The company reported a net loss of $66.5 million compared to net income of $22.5 million in the prior year. This $88.9 million swing was primarily due to a $148.5 million increase in operating expenses and $20.9 million in new interest expense.
• Expense Increases:
  • SG&A: Increased by $92.9 million to $264.6 million, driven by $34.8 million in transaction costs, accelerated share-based compensation ($18.4 million), and integration of the LUMRYZ commercial team.
  • R&D: Increased by $31.5 million to $103.3 million, reflecting advancement of the alixorexton Phase 3 program and LUMRYZ development.
  • Amortization: $11.7 million in amortization of acquired intangible assets (LUMRYZ) and $12.7 million in inventory step-up amortization were recorded.
• Balance Sheet Transformation: Total assets increased from $2.49 billion to $4.26 billion. Long-term debt increased from $0 to $1.51 billion following the execution of new Term Loan A and B facilities to fund the acquisition. Cash and restricted cash decreased significantly due to the $2.2 billion cash consideration paid for Avadel.

Outlook, Risks, and Unusual Items

• Debt Structure: The company entered a Credit Agreement on February 12, 2026, borrowing $1.525 billion. The Term Loan A matures in February 2031, and Term Loan B in August 2031. Interest rates are based on SOFR plus a margin (initially 2.75%).
• Contingent Consideration: A liability of $109.5 million was recorded for Contingent Value Rights (CVRs) related to the Avadel acquisition, with a potential maximum payout of $165.7 million upon achieving a specified milestone.
• Legal Proceedings:
  • LYBALVI ANDA Litigation: Patent infringement lawsuits filed against Teva, Apotex, and MSN Labs regarding generic versions of LYBALVI.
  • VIVITROL Antitrust: A class action lawsuit filed alleging fraudulent patent enforcement regarding VIVITROL.
  • Acorda Appeal: Oral arguments scheduled for May 2026 regarding an arbitration award dispute.
• Share Repurchases: The company repurchased approximately 1.0 million shares for $27.7 million. $172.3 million remains authorized under the program.

Investor Verification Checklist

• Verify the purchase price allocation for the Avadel acquisition, specifically the valuation of the LUMRYZ intangible asset ($1.77 billion) and the $513 million goodwill recorded.
• Monitor the contingent consideration liability ($109.5 million) for revaluation adjustments in future quarters based on the probability of achieving the CVR milestone.
• Assess the impact of inventory step-up amortization ($12.7 million in Q1) on future margins as the acquired LUMRYZ inventory is sold.
• Review the status of patent litigation surrounding LYBALVI and VIVITROL, as outcomes could materially affect future revenue streams.
• Confirm compliance with debt covenants (Secured Net Leverage Ratio and Interest Coverage Ratio) under the new $1.525 billion credit facility.